Related Experiment Video
Updated: Dec 31, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Kenji Chamoto1, Ryusuke Hatae1, Tasuku Honjo2
1Department of Immunology and Genomic Medicine, Kyoto University Graduate School of Medicine, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
Programmed cell death 1 (PD-1) blockade therapy shows promise in cancer treatment but faces challenges with patient response and side effects. Further research into mechanisms and biomarkers is crucial for improving efficacy and safety in cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Programmed cell death 1 (PD-1) signal receptor blockade has transformed cancer therapy.
- Current PD-1 blockade drugs face limitations including patient non-response, recurrence, and autoimmune side effects.
Purpose of the Study:
- To investigate the mechanisms underlying PD-1 blockade therapy.
- To identify novel biomarkers for predicting treatment response and monitoring adverse events.
- To explore combination therapy strategies to enhance PD-1 blockade efficacy.
Main Methods:
- This review synthesizes current research on PD-1 blockade mechanisms.
- It analyzes clinical data regarding patient response and side effects.
- It discusses the potential of combination therapies and biomarker development.
Main Results:
- PD-1 blockade therapy has revolutionized cancer treatment but has significant limitations.
- Patient non-response and autoimmune side effects remain major challenges.
- Combination therapies and novel biomarkers are essential for improving outcomes.
Conclusions:
- Addressing non-response and side effects is critical for advancing PD-1 blockade cancer immunotherapy.
- Further research into mechanisms, biomarkers, and combination strategies is needed.
- Optimizing PD-1 blockade therapy is central to improving cancer patient care globally.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

